Literature DB >> 31915256

Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease.

Taylor W Schmitz1,2, Hermona Soreq3, Judes Poirier4,5,6, R Nathan Spreng4,5,6,7.   

Abstract

Cholinergic inputs originating from the peripheral nervous system regulate the inflammatory immune responses of macrophages during clearance of blood-based pathogens. Because microglia are involved in clearing amyloid and tau pathology from the central nervous system, we hypothesized that cholinergic input originating from the basal forebrain might similarly regulate inflammatory immune responses to these pathologies in the aging brain. To explore this hypothesis, we leveraged the Alzheimer's Disease Neuroimaging Initiative dataset. Cognitively normal older male and female human adults were differentiated according to the relative concentration of phosphorylated tau and amyloid in their cerebrospinal fluid, yielding neurotypical and preclinical, cognitively healthy, subgroups. We then tracked these two groups longitudinally with structural MRI and biomarkers of inflammation, including soluble sTREM2 levels in the CSF and complement C3 expression in the blood transcriptome. Longitudinal loss of basal forebrain volume was larger in the preclinical compared with the neurotypical subgroup. Across preclinical adults, loss of basal forebrain volume was associated with greater longitudinal accumulation of sTREM2 and higher peripheral blood C3 expression. None of these relationships were attributable to degeneration in the whole-brain gray matter volume. Preclinical APOE e4 carriers exhibited the largest loss of basal forebrain volume and highest C3 expression. Consistent with the known anti-inflammatory influence of the peripheral cholinergic pathways on macrophages, our findings indicate that a loss of central cholinergic input originating from the basal forebrain might remove a key check on microglial inflammation induced by amyloid and tau accumulation.SIGNIFICANCE STATEMENT In the peripheral nervous system, cholinergic modulation holds the reactivity of macrophages to blood-based pathogens in check, promoting clearance while preventing runaway inflammation and immune-triggered cell death. Microglia are the brain's resident macrophages and play an important role in clearing accumulated amyloid and tau from neurons. Here, we demonstrate that a loss of cholinergic integrity in the CNS, indexed by longitudinal decreases of basal forebrain volume, interacts with multiple biomarkers of inflammation in cognitively normal older adults with abnormal amyloid and tau pathology. These interactions were not detected in cognitively normal older adults with "neurotypical" levels of amyloid and tau. An age-related loss of cholinergic neuromodulation may remove key checks on microglial reactivity to amyloid and tau.
Copyright © 2020 the authors.

Entities:  

Keywords:  amyloid; basal forebrain cholinergic system; complement C3; phosphorylated tau; preclinical Alzheimer's disease; soluble TREM2

Year:  2020        PMID: 31915256      PMCID: PMC7046458          DOI: 10.1523/JNEUROSCI.1184-19.2019

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

Review 1.  Cholino-ncRNAs modulate sex-specific- and age-related acetylcholine signals.

Authors:  Nimrod Madrer; Hermona Soreq
Journal:  FEBS Lett       Date:  2020-05-04       Impact factor: 4.124

2.  Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression.

Authors:  Nunzio Pomara; Davide Bruno; Chelsea Reichert Plaska; Anilkumar Pillai; Jaime Ramos-Cejudo; Ricardo Osorio; Bruno P Imbimbo; Amanda Heslegrave; Henrik Zetterberg; Kaj Blennow
Journal:  J Affect Disord       Date:  2021-03-09       Impact factor: 4.839

Review 3.  Microglia Biomarkers in Alzheimer's Disease.

Authors:  Peng-Fei Zhang; Hao Hu; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2021-03-12       Impact factor: 5.590

4.  iPSC-Derived Microglia for Modeling Human-Specific DAMP and PAMP Responses in the Context of Alzheimer's Disease.

Authors:  Ivanna Ihnatovych; Barbara Birkaya; Emily Notari; Kinga Szigeti
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

Review 5.  Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease.

Authors:  Jose L Martinez; Matthew D Zammit; Nicole R West; Bradley T Christian; Anita Bhattacharyya
Journal:  Front Aging Neurosci       Date:  2021-07-12       Impact factor: 5.702

6.  Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.

Authors:  Estrella Morenas-Rodríguez; Yan Li; Brigitte Nuscher; Nicolai Franzmeier; Chengjie Xiong; Marc Suárez-Calvet; Anne M Fagan; Stephanie Schultz; Brian A Gordon; Tammie L S Benzinger; Jason Hassenstab; Eric McDade; Regina Feederle; Celeste M Karch; Kai Schlepckow; John C Morris; Gernot Kleinberger; Bengt Nellgard; Jonathan Vöglein; Kaj Blennow; Henrik Zetterberg; Michael Ewers; Mathias Jucker; Johannes Levin; Randall J Bateman; Christian Haass
Journal:  Lancet Neurol       Date:  2022-04       Impact factor: 59.935

7.  Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment.

Authors:  Alexandra L Clark; Alexandra J Weigand; Kelsey R Thomas; Seraphina K Solders; Lisa Delano-Wood; Mark W Bondi; Rachel A Bernier; Erin E Sundermann; Sarah J Banks; Katherine J Bangen
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.160

Review 8.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

Review 9.  Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation.

Authors:  Rashmi Gamage; Ingrid Wagnon; Ilaria Rossetti; Ryan Childs; Garry Niedermayer; Rose Chesworth; Erika Gyengesi
Journal:  Front Cell Neurosci       Date:  2020-10-15       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.